Rituximab therapy in patients with refractory dermatomyositis or polymyositis: Differential effects in a real-life population

Rheumatology (United Kingdom)

Volumn 53, Issue 9, 2014, Pages 1630-1638

  Unger, Leonore ^a   Kampf, Susanne ^b   Lüthke, Kirsten ^c   Aringer, Martin ^b  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Schwerpunktpraxis Rheumatologie   (Germany)

Author keywords

B cell depletion; Dermatomyositis; Idiopathic inflammatory myositis; Interstitial lung disease; Polymyositis; Relapse; Rituximab; Safety

Indexed keywords

CREATINE KINASE; GLUCOCORTICOID; IMMUNOGLOBULIN G; PREDNISOLONE; RITUXIMAB;

ADULT; AGED; ANTISYNTHETASE SYNDROME; ARTICLE; ASPIRATION PNEUMONIA; BRADYCARDIA; CAUSE OF DEATH; CHOLECYSTITIS; CLINICAL ARTICLE; DERMATOMYOSITIS; DISEASE DURATION; DRUG EFFECT; ERYSIPELAS; FEMALE; HERPES ZOSTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; KIDNEY INJURY; LUNG ALVEOLITIS; LUNG FUNCTION TEST; MALE; MIDDLE AGED; MUSCLE STRENGTH; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; REFRACTORY DERMATOMYOSITIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE; URINARY TRACT INFECTION; VERY ELDERLY; YOUNG ADULT;

EID: 84906825405     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu024     Document Type: Article

References (26)

1. Couderc M, Gottenberg JE, Mariette X et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology 2011;50:2283-9.
2. Mahler EA, Blom M, Voermans NC et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology 2011;50:2206-13.
3. Bader-Meunier B, Decaluwe H, Barnerias C et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French autoimmunity and rituximab registry. J Rheumatol 2011;38:1436-40.
4. Tony HP, Burmester G, Schulze-Koops H et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011;13:R75.
5. Valiyil R, Casciola-Rosen L, Hong G et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 2010;62:1328-34.
6. Sem M, Molberg O, Lund MB et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009;48:968-71.
7. Cooper MA, Willingham DL, Brown DE et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007;56: 3107-11.
8. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007;34:1864-8.
9. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763-7.
10. Dinh HV, McCormack C, Hall S et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007; 56:148-53.
11. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006;33:1021-6.
12. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
13. Perosa F, Prete M, Racanelli V et al. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 2010;267:260-77.
14. Gunawardena H, Betteridge ZE, McHugh NJ. Myositisspecific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 2009; 48:607-12.
15. Grundtman C, Malmstrom V, Lundberg IE. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther 2007; 9:208.
16. Brouwer R, Hengstman GJ, Vree Egberts W et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
17. Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis- specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-74.
18. Oddis CV, Reed AM, Aggarwal R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
19. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344-7.
20. Miller FW, Rider LG, Chung YL et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-73.
21. Aggarwal R, Reed AM, Ascherman DP et al. Clinical and serologic predictors of response in rituximab-treated refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM)-the RIM study [abstract]. Arthritis Rheum 2012;64(Suppl):S682-3.
22. Marie I, Dominique S, Janvresse A et al. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 2012; 106:581-7.
23. van Vollenhoven RF, Emery P, Bingham CO III et al. Longterm safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496-502.
24. Rider LG, Koziol D, Giannini EH et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 2010;62:465-72.
25. Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol 2012;24:635-41.
26. Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol 2011;24: 457-62.